(Albany, US) DelveInsight's "Adeno-Associated Virus Vectors in Gene Therapy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Adeno-Associated Virus Vectors in Gene Therapy, historical and forecasted epidemiology as well as the Adeno-Associated Virus Vectors in Gene Therapy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some facts of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy report:
- The AAV based gene therapies market size in the United States was valued to be USD 428 million in 2019.
- In the year 2020, the total prevalent cases of selected indications for AAV Gene Therapies were 2,863,103 in the 7MM.
- In EU-5 countries the highest number of prevalent cases were in Germany, i.e., 441,670 in the year 2020.
- The total prevalent cases of Hemophilia A and Hemophilia B were reported to be 43,243 and 10,811 in 2020.
- In the United Kingdom, the total treated cases of Parkinson’s disease and Spinal Muscular Atrophy were 32,255 and 949, respectively, in the year 2020.
Get more comprehensive insights into how Adeno-Associated Virus (AAV) Vector-Based Gene Therapy epidemiological trends are impacting current and forecasted Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market @ Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Epidemiology Analysis and Forecast
Key Benefits of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Report:
- The report covers the descriptive overview of Adeno-Associated Virus Vectors in Gene Therapy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Adeno-Associated Virus Vectors in Gene Therapy epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Adeno-Associated Virus Vectors in Gene Therapy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Adeno-Associated Virus Vectors in Gene Therapy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Adeno-Associated Virus Vectors in Gene Therapy market
To know more about the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market report offerings, click here @ Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Insight
The key players in Adeno-Associated Virus Vectors in Gene Therapy market are:
- Valoctocogene Roxaparvovec (BMN 270): BioMarin Pharmaceutical: Phase III
- PF-06939926: Pfizer: Phase III
- Fidanacogene elaparvovec: Pfizer (initiated by Spark Therapeutics): Phase III
- AMT-061: uniQure/CSL Behring: Phase III
- Timrepigene emparvovec (BIIB111): NightstaRx Ltd, a Biogen Company: Phase III
- Giroctocogene fitelparvovec (SB-525): Pfizer (previously Sangamo Biosciences): Phase III
- BIIB112 (AAV8-RPGR): NightstaRx Ltd, a Biogen Company: Phase II/III
- NLX P101 (AAV-GAD): MeiraGTx: Phase II
- VY-AADC (NBIb-1817/ AAV2-hAADC): Neurocrine Biosciences/ Voyager Therapeutics: Phase II
- SPK-8011: Roche (previously Spark Therapeutics)/Pfizer: Phase I/II
- ST-920: Sangamo Therapeutics: Phase I/II
- FLT190: Freeline Therapeutics: Phase I/II
- SPK-3006 (AAV-sec-GAA): Spark Therapeutics: Phase I/II
- ACTUS-101: Asklepios Biopharmaceutical (Actus Therapeutics): Phase I/II
- AT845: Audentes Therapeutics: Phase I/II
- SRP-9001: Roche/Sarepta Therapeutics: Phase I/IIa
- HORA-PDE6B: Horama S.A.: Phase I/II
- AAV-RPGR (AAV2/5-RPGR): MeiraGTx UK II Ltd: Phase I/II
- RGX-121: RegenxBio: Phase I/II
- SB-913: Sangamo Therapeutics: Phase I/II
- AT-GTX-501 (scAAV9.CB.CLN6): Amicus Therapeutics: Phase I/IIa
- AT-GTX-502 (scAAV9.P546.CLN3): Amicus Therapeutics: Phase I/IIa
To know in detail about the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy treatment landscape, click here: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy companies and drugs
Adeno-associated virus (AAV) belongs to the genus Dependoparvovirus within the family Parvoviridae. Its life cycle is dependent on the presence of a helper virus, such as AdV, hence its name and taxonomy classification. AAV is found in multiple vertebrate species, including human and non-human primates (NHPs). The current consensus is that AAV does not cause any human diseases. It is composed of an icosahedral protein capsid of ~26 nm in diameter and a single-stranded DNA genome of ~4.7 kb that can either be the plus (sense) or minus (anti-sense) strand.AAV vectors are the leading platform for gene delivery for the treatment of a variety of human diseases.
Recent advances in developing clinically desirable AAV capsids, optimizing genome designs, and harnessing revolutionary biotechnologies have contributed substantially to the growth of the gene therapy field.
Preclinical and clinical successes in AAV-mediated gene replacement, gene silencing, and gene editing have helped AAV gain popularity as the ideal therapeutic vector, with few AAV-based therapeutics gaining regulatory approval in Europe and the United States.
Do you want to know how much market share the emerging therapies are going to capture by 2032? Contact: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Outlook
Table of Contents:
1. Key Insights
2. Executive Summary of Adeno-Associated Virus Vectors in Gene Therapy
3. Competitive Intelligence Analysis for Adeno-Associated Virus Vectors in Gene Therapy
4. Adeno-Associated Virus Vectors in Gene Therapy: Market Overview at a Glance
5. Adeno-Associated Virus Vectors in Gene Therapy: Disease Background and Overview
6. Patient Journey
7. Adeno-Associated Virus Vectors in Gene Therapy Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Unmet Needs
10. Key Endpoints of Adeno-Associated Virus Vectors in Gene Therapy Treatment
11. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Marketed Products
12. Emerging Adeno-Associated Virus (AAV) Vector-Based Gene Therapies
13. Adeno-Associated Virus Vectors in Gene Therapy: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Outlook
16. Access and Reimbursement Overview of Adeno-Associated Virus Vectors in Gene Therapy
17. KOL Views
18. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
19. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
To know more about Emerging Adeno-Associated Virus (AAV) Vector-Based Gene Therapies, click here: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Treatment Scenario
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services
